Sling Therapeutics Announces Publication of New Data Highlighting Differentiated Mechanism of Action of Oral IGF-1R Inhibitor Linsitinib in Thyroid Eye Disease
Preclinical findings published in Frontiers in Immunology demonstrate linsitinib’s ability to inhibit key drivers of thyroid eye disease through intracellular IGF-1R blockade, with distinct effects compared to antibody-based treatment Poster presentation at the 2026 American Thyroid Association (ATA) Annual Meeting…